LisaMDunkleMDFAAP, FIDSA
Pediatric Infectious Disease • Madison, CTVice President, Global Medical Lead for coronavirus vaccine, Novavax, Inc
Dr. Dunkle is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
12 Richborough Road
Madison, CT 06443
Summary
- Dr. Lisa Dunkle is a pediatric infectious disease specialist in Meriden, CT. She received her medical degree from Johns Hopkins University School of Medicine and has been in practice 45 years. She is experienced in influenza, pediatric hiv/aids, pediatric infectious disease, clinical research, and anti-hiv agents.
Education & Training
Washington University/B-JH/SLCH ConsortiumResidency, Pediatrics, 1972 - 1976
Johns Hopkins University School of MedicineClass of 1972
Certifications & Licensure
CT State Medical License 1989 - 2025
MO State Medical License 1976 - 2025- American Board of Pediatrics Pediatrics
Awards, Honors, & Recognition
- Distinguished Alumna Award Johns Hopkins School of Medicine, 2011
Clinical Trials
- Safety and Antiviral Activity Study of ACH-126,443 (Beta-L-Fd4C) in Treatment-naive Adults With Chronic Hepatitis B Virus Infection Start of enrollment: 2002 Feb 01
Publications & Presentations
PubMed
- 30 citationsRandomized Comparison of Immunogenicity and Safety of Quadrivalent Recombinant Versus Inactivated Influenza Vaccine in Healthy Adults 18-49 Years of Age.Lisa M. Dunkle, Ruvim Izikson, Peter A. Patriarca, Karen L. Goldenthal, Derek Muse
The Journal of Infectious Diseases. 2017-12-05 - 93 citationsSafety, efficacy, and immunogenicity of Flublok in the prevention of seasonal influenza in adults:Manon M.J. Cox, Ruvim Izikson, Penny Post, Lisa M. Dunkle
Therapeutic Advances in Vaccines. 2015-07-01 - 21 citationsRandomized comparison of the safety of Flublok(®) versus licensed inactivated influenza vaccine in healthy, medically stable adults ≥ 50 years of age.Ruvim Izikson, David J. Leffell, S. Allan Bock, Peter A. Patriarca, Penny Post
Vaccine. 2015-11-27
Press Mentions
- The Power of Diversity in Clinical TrialsMarch 6th, 2023
- Covid-19: NVX-CoV2373 Vaccine Highly Effective in PREVENT-19 TrialDecember 17th, 2021
- Tribes Were Often Overlooked in COVID-19 Vaccine Trials, Frustrating Indigenous LeadersMay 25th, 2021
- Join now to see all
Professional Memberships
- Fellow
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
